Allergan Inc $133.92

up +2.46


17/4/2014 06:40 PM  |  NYSE : AGN  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get AGN Trend Analysis - it has underperformed the S&P 500 by 2%

Partner Headlines

  1. Market Wrap For April 16: Markets Hold On To Gains An Positive Yellen Comments ...

    Benzinga
  2. Stocks On Track For Third Gain; Allergan Rises

    IBD
  3. Benzinga's Volume Movers

    Benzinga
  4. Alexion, Biogen Among Leading Big-Cap Biotechs

    IBD
  5. Market Wrap For March 28: Markets Still Positive Despite Giving Up Early ...

    Benzinga
  6. Abbott Capturing Incremental Market Share

    GuruFocus
  7. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest ...

    Benzinga
  8. Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains

    Benzinga
  9. Weekly CEO Sells Highlight: Cardinal Health, Envision Healthcare Holdings, ...

    GuruFocus
  10. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest ...

    Benzinga
  11. Morgan Stanley Says Allergan Management is Still Optimistic

    Benzinga
  12. Jazz, Valeant Pace Highly Rated Ethical Drugs Group

    IBD
  13. Allergan tops, guides Q1 low

    IBD
  14. Earnings Scheduled For February 5, 2014

    Benzinga
  15. UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals

    Benzinga
  16. Morgan Stanley Maintainson Allergan, Changes PT

    Benzinga
  17. Allergan

    IBD
  18. Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

    Benzinga
  19. Stocks Add To Gains; Allergan Jumps On Ruling

    IBD
  20. Allergan, Medytox Close Licensing Agreement

    Benzinga
  21. Do-Nothing Breakouts Can Have Three Causes

    IBD
  22. Stock with High Forward Rate of Return, Donald Yacktman's Measure

    GuruFocus
  23. Stocks with High Forward Rate of Return, Donald Yacktman's Measure

    GuruFocus
  24. Benzinga's Top Upgrades

    Benzinga
  25. Cowen Suggests Truth to Allergan Rumors

    Benzinga
  26. Allergan said to gain 3 patents

    IBD
  27. New Allergan Patents May Fend Off Restasis Rivals

    IBD
  28. Merger Monday Lives Up To Its Name: 33.175 Billion In Deals

    Benzinga
  29. UPDATE: Credit Suisse Raises PT on Allergan on Compelling Turnaround Story ...

    Benzinga
  30. UPDATE: BTIG Research Initiates Coverage on Allergan as Lots of Shots on ...

    Benzinga
  31. List: $34B In Pharma Sales Lose Patent in 2014

    YCharts
  32. Where J&J $2.2B Settlement Fits Among Biggest

    YCharts
  33. Best Return On Invested Capital In Pharma?

    YCharts
  34. Insiders Are Buying Ophthotech

    GuruFocus
  35. Drugmaker Akorn Becoming Mighty Oak In Hi-Tech Merger

    IBD
  36. Valeant Eyes New Growth Platform With Bausch & Lomb

    IBD
  37. Weatherford, Copart And Others Insiders Have Been Buying (AYR, CPRT, OPK, ...

    Benzinga
  38. Allergan, Medytox to Enter Licensing Agreement

    Benzinga
  39. The FDA approved

    IBD
  40. Top 4 Large-Cap Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  41. Sands Capital Management Update, Sells AAPL, Cuts GOOG and Others

    GuruFocus
  42. Valeant Raises Guidance With Bausch & Lomb Merger

    IBD
  43. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom ...

    Benzinga
  44. 2013: Year of the Mega Deal

    Benzinga
  45. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest ...

    Benzinga
  46. UPDATE: Stifel Nicolaus Raises PT to $118 on Allergan on Solid 2013 Outlook

    Benzinga
  47. UPDATE: Jefferies Raises PT on Allergan on Q4 EPS

    Benzinga
  48. Botox lifts Allergan earnings

    IBD
  49. Allergan Reports Mixed Q4, But Bullish Margin Outlook

    IBD
  50. Estee Lauder Beats, Allergan EPS Tops On Botox

    IBD
Trading Center